All procedures completed in the study are free of charge. Alzheimer's Disease Study Recruitment begins soon for a new medication study aimed at slowing the rate of decline of cognitive function in patients with Alzheimer's disease. Participants will be randomly assigned to receive either rofecoxib, naproxen, or a sugar pill. To participate, individuals must be ages 55 to 90. Participants may not reside in a skilled nursing facility.
All procedures completed in the study are free of charge.